Roche silently whisks away its lead $1.7B Seragon drug in a Q1 footnote
Close to three years ago Roche’s Genentech team came in and bought out Seragon from Rich Heyman for $725 million in cash and another …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
